R&D channel feed

Mod­er­na CEO Ban­cel ac­knowl­edges a set­back, but stays fo­cused on an up­beat as­sess­ment of 2019

6 years ago

The first biotech IPO of the new decade has land­ed — and of course it's an­oth­er can­cer drug de­vel­op­er

6 years ago
Financing

As ques­tions swirl around lead drug, Fi­bro­Gen (and As­traZeneca) find a new cham­pi­on from Big Phar­ma

6 years ago
People

J&J drops its op­tion on Proven­tion Bio drug af­ter tri­al fail­ure

6 years ago

Re­gen­eron brings out the bud­get ax as ex­ecs cut staff in the wake of re­vis­ing al­liance with Sanofi

6 years ago

Cash-strapped No­van takes a hard knock as mol­lus­cum drug fiz­zles in late-stage tri­als

6 years ago

In­cyte takes a beat­ing as a key PhI­II study flops in their lat­est painful set­back — block­buster hopes crushed

6 years ago

Durect shares stum­ble as top drug fails mid-stage tri­al

6 years ago

Tough times for Tecen­triq as NICE once again slaps down Roche's im­munother­a­py — slight ben­e­fit not worth price

6 years ago

Biotech bil­lion­aire spends $88M to re­or­ga­nize his long-suf­fer­ing bio­engi­neer­ing busi­ness­es, hands off CEO role

6 years ago

Decades old tu­ber­cu­lo­sis vac­cine di­rect­ly in­ject­ed in­to veins could tur­bocharge pro­tec­tion, mon­key study finds

6 years ago

Savara gets FDA break­through sta­tus de­spite large, late-stage fail­ure

6 years ago
FDA+

Wave spot­lights ‘pos­i­tive’ da­ta on Hunt­ing­ton’s drug, but stock takes a beat­ing as Roche, Io­n­is ri­val stays in front

6 years ago

An­tibi­otics apoc­a­lypse: Melin­ta files for bank­rupt­cy pro­tec­tion as a plague of woes af­flicts the field

6 years ago

On a spree, Astel­las bags a next-gen, Park­er-backed CAR-T plat­form with $665M buy­out deal

6 years ago

Biotech takes a Christ­mas beat­ing af­ter safe­ty fears force re­searchers to halt all hep B stud­ies

6 years ago

Spec­trum shares crater as first round of piv­otal da­ta for their TKI falls short of pri­ma­ry end­point

6 years ago

The top 10 most pop­u­lar End­points News pieces of 2019 — go­ing vi­ral is a whole new game in bio­phar­ma now

6 years ago

FDA makes it of­fi­cial, once again re­ject­ing bat­tered Cor­re­vio’s heart drug

6 years ago

Gilead gets ball rolling on JAKs game in Japan

6 years ago

Al­ler­gan gets a win: FDA ap­proves ubro­gepant as cas­cade of treat­ments re­shape mi­graine field

6 years ago

Ei­sai scores an FDA ap­proval for a home­grown sleep drug

6 years ago
FDA+

Gilead sub­mits an NDA for its big block­buster hope­ful

6 years ago

With eye on win­ning over FDA in the wake of RTF, Zo­genix pub­lish­es new Fin­tepla da­ta

6 years ago
First page Previous page 216217218219220221222 Next page Last page
A service from the Financial Times